As if being sick weren’t bad enough, there’s also the fear of frequent injections, side effects and overdosing on you medication.
Now a team of researchers from University of Copenhagen, Department of Chemistry, Nano-science center and the Institut Laue-Langevin (ILL), have shown that reservoirs of anti-viral pharmaceuticals could be manufactured to bind specifically to infected tissue such as cancer cells for the slow concentrated delivery of drug treatments. The new research is published in ACS Macro Letters.
Smaller doses, less injections and fewer side effects
The findings, from Dr Marité Cárdenas (Copenhagen) and Dr Richard Campbell and Dr Erik Watkins (ILL), came as a result of neutron reflectometry studies at the world’s leading neutron source in Grenoble, France. They could provide a way to reduce dosages and the frequency of injections administered to patients undergoing a wide variety of treatments, as well as minimising side effects of over-dosing.
Fats and branches hold medicine for longer
The attachment of reservoirs of therapeutic drugs to cell membranes for slow diffusion and continuous delivery inside the cells is a major aim in drug R&D. A promising candidate for packaging up and carrying such concoctions of drugs are a group of self-assembled liquid crystalline particles. Composed of fatty molecules known as phospholipids and tree-like macromolecules called dendrimers which have many branches, the particles form spontaneously and have the capacity to soak up and carry large quantities of drug molecules for prolonged diffusion. They are also known for their ability to bind to cellular membranes.
First treatment close to market
The first treatments using such particles are close to market through products incorporating a similar formulation called Cubosomes (cubic phase nanoparticles). Developed and commercialized by Swedish start-up Camarus Ab, its FluidCrystal® nanoparticles promise months of drug delivery from a single injection and the possibility of tuning the delivery to intervals of anything from daily to once monthly. However, a key requirement for optimal application of these formulations is a detailed understanding of how they interact with cellular membranes.
This was the focus of work involving a collaboration between Dr Marité Cárdenas (Copenhagen) and Dr Richard Campbell and Dr Erik Watkins (ILL). In this experiment the team used neutrons to analyse the interaction of the liquid crystalline particles with a model cellular membrane whilst varying two parameters:
- Gravity – to see how the interaction changed if the aggregates attacked the cell membrane from below as opposed to above
- Electrostatics – how the balance between the contrasting positive and negative charges of the aggregate and membrane affect the interaction
Detailed surface information with bouncing electrons
The team utilised a technique known as neutron reflectometry whereby beams of neutrons are skimmed off a surface and the reflectivity measured is used to infer detailed information about the surface, including the thickness, detailed structure and composition of any layers beneath. These experiments were carried out on the FIGARO instrument at the ILL in Grenoble which offers unique reflection up vs. down modes that allowed the team to examine the top and bottom surfaces, alternating the samples on a two hourly basis during a 30 hour sampling period.
Small changes to charge of molecules could have major effects
The interaction of the liquid crystalline particles with the membrane was shown to be driven by the charge on the mode cell wall. Subtle changes in the amount of negative charge on the membrane wall encouraged the tree-like dendrimer molecules to penetrate through allowing the rest of the molecule to bind to the surface, forming an attached reservoir. The sensitivity of the interaction to small changes in charge suggests that simple adjustments to the proportion of charged lipids and macromolecules could optimise this process. In the future this characteristic could also provide a mechanism to focus the treatment at targeted cells such as those infected by cancer which are thought to have a more negative charge density than healthy cells.
“Cancerous cells have an imbalance that gives them a different molecular composition and overall different physical properties to normal healthy cells”, explains Dr Cardenas. “Whilst all cells are negative, cancerous cells tend to be more negatively charged than healthy ones due to a different composition of fatty molecules on their surface. This is a property that we believe could be exploited in future research into delivery mechanisms involving the attachment of lamellar liquid crystalline particles. Our next step is to introduce the drug itself into the reservoirs and make sure it can move across the membrane. This work paves the way for cell tests and clinical trials in the future exploiting our methodology”
The Latest on: Cancer treatment
via Google News
The Latest on: Cancer treatment
- Non-Small Cell Lung Cancer Treatment Market to Surpass US$ 39,395.2 Million, Globally, by the end of 2027 - CMIon March 24, 2020 at 5:19 pm
코스피(유가증권시장) 지수가 25일 장 시작과 동시에 4% 넘게 오르며 1700선 턱밑까지 밀고 올라갔다. 미국 중앙은행의 무제한 양적완화와 금융 지원, 한국 정부의 100조원 규모 금융시장 안정 대책 등이 쏟아지며 시장 불안이 완화한 것으로 분석된다. 25일 ...
- PSMA PET/CT Better Detects Prostate Cancer Spreadon March 24, 2020 at 2:02 pm
"Taken together, our findings indicate that PSMA-PET/CT scans offer greater accuracy than conventional imaging and can better inform treatment decisions," Hofman said in a statement. "We recommend ...
- Some cancer patients face delayed surgeries and scaled-back treatments as the coronavirus advanceson March 24, 2020 at 11:12 am
Truck drivers are still driving hours each day, but are changing the way they do things in response to the coronavirus pandemic.
- Ear Cancer Treatment Market | Top Companies - Oncology Venture, Merck and Company Inc., F. Hoffmann-La Roche, Amgen Inc., Celgene Corporationon March 24, 2020 at 9:54 am
Mar 24, 2020 (Industry News Wire via COMTEX) -- Ear Cancer Treatment Market The Ear Cancer Treatment market report offers a detailed assessment of the global ...
- Prostate Cancer Treatment Market Revenue to Hit $9,904 Million By 2026on March 24, 2020 at 4:30 am
Portland, OR, Mar 24, 2020 (GLOBE NEWSWIRE via COMTEX) -- Portland, OR, March 24, 2020 (GLOBE NEWSWIRE) -- Big Market Research offers an extensive research ...
- Concure Oncology raises $2.5M for breast cancer treatment that fights tumors with radioactive seedson March 23, 2020 at 1:10 pm
Concure Oncology has raised $2.5 million in new capital for breast cancer treatment that uses radioactive seeds to prevent tumors from growing. With the new funding, announced last week, the Mercer ...
- Root canal procedures do not cause cancer: This is whyon March 23, 2020 at 11:46 am
suggesting a link between dental work and the development of cancer. With the American Association of Endodontists (AAE) stating that over 15 million root canal treatments are carried out every year ...
- New imaging approach may alter prostate cancer treatmenton March 23, 2020 at 9:00 am
Le troisième acte entre les boxeurs Tyson Fury et Deontay Wilder ne se déroulera pas avant plusieurs mois. Les organisateurs ont jugé préférable de ne pas maintenir le combat du fait de l’épidémie de ...
- Coronavirus canceled her chemotherapy. Should cancer patients still go to appointments?on March 23, 2020 at 7:57 am
Soon after she was diagnosed with late-stage pancreatic cancer in January, Janet Glass began going every other week to Englewood Health in New Jersey for a three-day chemotherapy ...
- p300/CBP inhibition enhances the efficacy of programmed death-ligand 1 blockade treatment in prostate canceron March 22, 2020 at 6:14 pm
All prices are NET prices. VAT will be added later in the checkout. Fig. 1: Class I HDACs inhibition increased PD-L1 expression in metastatic PCa cells. Fig. 2: Upregulated PD-L1 by HDAC inhibition ...
via Bing News